中国感染控制杂志
中國感染控製雜誌
중국감염공제잡지
CHINESE JOURNAL OF INFECTION CONTROL
2014年
6期
353-355
,共3页
免疫性血小板减少性紫癜%幽门螺杆菌%儿童%免疫功能
免疫性血小闆減少性紫癜%幽門螺桿菌%兒童%免疫功能
면역성혈소판감소성자전%유문라간균%인동%면역공능
Kex words] immune thrombocytopenic purpura%Helicobacter pylori%child%immune function
目的：分析免疫性血小板减少性紫癜合并幽门螺杆菌感染患者免疫功能的变化及治疗效果。方法选取某院2011年3月-2012年3月收治的80例血小板减少性紫癜患儿作为观察组，根据患儿是否感染幽门螺杆菌，分为感染亚组和未感染亚组；同时，选择同期80例健康儿童作为对照组，比较各组间淋巴细胞亚群测定结果、临床疗效以及复发率。结果观察组幽门螺杆菌阳性率为55．00％（44/80），显著高于对照组的2．50％（2/80），差异有统计学意义（χ2＝12．48，P＝0．008）。各组间CD4＋、CD4＋/CD8＋以及CD19＋T淋巴细胞比较，差异有统计学意义（均P＜0．05）；其中感染亚组患儿CD4＋[（13．40±4．65）％]、CD4＋/CD8＋T淋巴细胞[（0．69±0．18）％]明显低于未感染亚组[分别为（28．56±3．82）％、（1．04±0．23）％]，而CD19＋T淋巴细胞[（45．21±10．20）％]则明显高于未感染亚组[（22．05±2．23）％]；未感染亚组和感染亚组患儿CD4＋、CD4＋/CD8＋T淋巴细胞明显低于对照组[分别为（40．20±3．42）％、（1．54±0．42）％]，而CD19＋T淋巴细胞明显高于对照组[（11．02±2．89）％]。感染亚组和未感染亚组患儿治疗有效率分别为90．91％、91．67％，两组差异无统计学意义（P＞0．05）。感染亚组患儿经抗幽门螺杆菌感染治疗后血小板减少性紫癜复发率（20．45％）显著低于未感染亚组患儿（30．56％；χ2＝6．396，P＝0．038）。结论通过免疫功能检测，有助于临床诊断免疫性血小板减少性紫癜合并幽门螺杆菌的感染。
目的：分析免疫性血小闆減少性紫癜閤併幽門螺桿菌感染患者免疫功能的變化及治療效果。方法選取某院2011年3月-2012年3月收治的80例血小闆減少性紫癜患兒作為觀察組，根據患兒是否感染幽門螺桿菌，分為感染亞組和未感染亞組；同時，選擇同期80例健康兒童作為對照組，比較各組間淋巴細胞亞群測定結果、臨床療效以及複髮率。結果觀察組幽門螺桿菌暘性率為55．00％（44/80），顯著高于對照組的2．50％（2/80），差異有統計學意義（χ2＝12．48，P＝0．008）。各組間CD4＋、CD4＋/CD8＋以及CD19＋T淋巴細胞比較，差異有統計學意義（均P＜0．05）；其中感染亞組患兒CD4＋[（13．40±4．65）％]、CD4＋/CD8＋T淋巴細胞[（0．69±0．18）％]明顯低于未感染亞組[分彆為（28．56±3．82）％、（1．04±0．23）％]，而CD19＋T淋巴細胞[（45．21±10．20）％]則明顯高于未感染亞組[（22．05±2．23）％]；未感染亞組和感染亞組患兒CD4＋、CD4＋/CD8＋T淋巴細胞明顯低于對照組[分彆為（40．20±3．42）％、（1．54±0．42）％]，而CD19＋T淋巴細胞明顯高于對照組[（11．02±2．89）％]。感染亞組和未感染亞組患兒治療有效率分彆為90．91％、91．67％，兩組差異無統計學意義（P＞0．05）。感染亞組患兒經抗幽門螺桿菌感染治療後血小闆減少性紫癜複髮率（20．45％）顯著低于未感染亞組患兒（30．56％；χ2＝6．396，P＝0．038）。結論通過免疫功能檢測，有助于臨床診斷免疫性血小闆減少性紫癜閤併幽門螺桿菌的感染。
목적：분석면역성혈소판감소성자전합병유문라간균감염환자면역공능적변화급치료효과。방법선취모원2011년3월-2012년3월수치적80례혈소판감소성자전환인작위관찰조，근거환인시부감염유문라간균，분위감염아조화미감염아조；동시，선택동기80례건강인동작위대조조，비교각조간림파세포아군측정결과、림상료효이급복발솔。결과관찰조유문라간균양성솔위55．00％（44/80），현저고우대조조적2．50％（2/80），차이유통계학의의（χ2＝12．48，P＝0．008）。각조간CD4＋、CD4＋/CD8＋이급CD19＋T림파세포비교，차이유통계학의의（균P＜0．05）；기중감염아조환인CD4＋[（13．40±4．65）％]、CD4＋/CD8＋T림파세포[（0．69±0．18）％]명현저우미감염아조[분별위（28．56±3．82）％、（1．04±0．23）％]，이CD19＋T림파세포[（45．21±10．20）％]칙명현고우미감염아조[（22．05±2．23）％]；미감염아조화감염아조환인CD4＋、CD4＋/CD8＋T림파세포명현저우대조조[분별위（40．20±3．42）％、（1．54±0．42）％]，이CD19＋T림파세포명현고우대조조[（11．02±2．89）％]。감염아조화미감염아조환인치료유효솔분별위90．91％、91．67％，량조차이무통계학의의（P＞0．05）。감염아조환인경항유문라간균감염치료후혈소판감소성자전복발솔（20．45％）현저저우미감염아조환인（30．56％；χ2＝6．396，P＝0．038）。결론통과면역공능검측，유조우림상진단면역성혈소판감소성자전합병유문라간균적감염。
Objective To analyze the change in immune function and therapeutic effectiveness of children with im-mune thrombocytopenic purpura and Helicobacter pylori(H. pylori)infection. Methods Eighty hospitalized chil-dren with thrombocytopenic purpura between March 2011 and March 2012 were as observation group,and then sub-divided into infected group and non-infected group according to whether they were infected with H. pylori;80 healthy children were as control group . Lymphocyte subsets ,clinical therapeutic effectiveness and recurrence rate among three groups were compared. Results The positive rate of H. pylori in observation group was significantly higher than control group(55.00% [44/80]vs 2.50% [2/80];χ2= 12.48,P= 0.008). There was significant differences in CD4+,CD4+/CD8+ ,and CD19+T lymphocyte among three groups (all P<0.05);CD4+ and CD4+/CD8+ T lymphocyte in infected group was significantly lower than non-infected group respectively ([13.40±4.65]% )vs [28.56± 3.82]% ;[0.69±0.18]% vs [1.04±0.23]% ),and CD19+T lymphocyte in infected group was significantly higher than non-infected group ([45.21±10.20]% vs [22.05±2.23]% );CD4+ and CD4+/CD8+T lymphocyte in non-in-fected group and infected group was significantly lower than control group ([40.20±3.42]% ,[1.54±0.42]% respec-tively),and CD19+T lymphocyte was significantly higher than control group ([11.02±2.89]% ). The overall therapeu-tic effectiveness in infected group and non-infected group was 90.91% and 91.67% respectively(P>0.05). The recur-rence rate of thrombocytopenic purpura after anti-H.pylori infection therapy in infected group was significantly lower than non-infected group (20.45% vs 30.56% ;χ2= 6.396,P= 0.038). Conclusion Detection of immune function is helpful for clinical diagnosis of H. pylori infection associated with immune thrombocytopenic purpura .
